novel GPR52 agonist HTL00411718 to modulate centrally mediated locomotor activity in response to A2A receptor

September 2022 "Background G protein-coupled receptor (GPCR) is the most targeted protein family by

January 2022 "G-protein-coupled receptors’ star has been on the rise in biotech in recent years as researchers

co-founder "J an 27, 2022 07:00am Septerna wants to spark a second golden age in G-protein-coupled receptor

post-translational processing, release from dense core vesicles, and ability to activate G-protein-coupled receptors

biopharmaceutical company with an innovative approach to drug discovery based on targeting G Protein Coupled Receptors

TRV045 is the Company’s novel S1P1 receptor modulator being developed as a potential treatment for diabetic

regulates S1PR1 trafficking and the morphology, cell cycle and survival of PC12 cells GLP-1 and GIP receptors mobilization when combined with propranolol Discovery of 3-Phenyl Indazole-Based Novel Chemokine-like Receptor

pain-relieving compounds that, like morphine and other drugs, provide relief via activation of opioid receptors

Dipraglurant selectively targets the metabotropic glutamate receptor subtype 5 (mGlu5) through allosteric

The targets, including G protein-coupled receptors (GPCRs), intracellular protein complexes and solute

The vision is to develop novel muscarinic receptor agonists for schizophrenia and other neuropsychiatric

In one example, to study a G protein coupled receptor (GPCR), we used one antagonist as probe and multiple

drug discovery and development, announced today that it has moved a selective and potent M4 muscarinic receptor

uses conformationally selective VHH antibodies – ConfoBodies® – to stabilize GPCRs (G protein-coupled receptors

Several neurotransmitters and neuromodulators, acting through G-protein-coupled receptors (GPCRs), fine-tune outcomes suggest that LPA and several neurotransmitters impact MN IME via Gαi/o/Gαq-protein-coupled receptors

September 2022 "Class A (rhodopsin-like) G protein-coupled receptors (GPCRs) are constitutive phospholipid

results in the production of bioactive C3a, a product of C3 cleavage, which interacts with membrane-bound receptor

, a drug discovery and development company unlocking the therapeutic potential of G Protein-Coupled Receptors

pleasure to announce the fourth hybrid symposium on regulatory autoantibodies targeting G-protein-coupled receptors

will discuss the regulation of mTORC1 by upstream stimuli, with a specific focus on G-protein coupled receptor

October 2022 "The very large G protein-coupled receptor (VLGR1, ADGRV1) is the largest member of the

screening, drug efficacy analyses, and toxicity studies; technologies that stabilize G protein–coupled receptors

authorization for the Company’s TAVNEOS (avacopan), an orally administered selective complement 5a receptor

June 2022 "G protein-coupled receptors (GPCRs) represent a major therapeutic target class as they play

axis, have entered a strategic research collaboration to identify and validate novel G protein-coupled receptor

CQ: chloroquine; E2F1: E2F transcription factor 1; FBS: fetal bovine serum; GPCRs: G protein-coupled receptors p62: sequestosome 1; STAT: signal transducer and activator of transcription; TACR1/NK1R: tachykinin receptor

Taking advantage of a striking deficit of both NPS receptor (NPSR1) and NPS precursor knockout mice in